Rebecca Chopp

, PhD

Alzheimer's Activist and Educator

Rebecca Chopp, PhD, is an Alzheimer's activist and educator. She co-founded Voices of Alzheimer's, serves as a member of the board of the National Alzheimer's Association, and is a member of the board of the Colorado Chapter of the Alzheimer's Association. She is a frequent speaker and writer on timely diagnosis, research for a cure, access to and affordability of drugs, and lifestyle interventions for those with Alzheimer's. Her book Still Me will be published in 2024.

Before Dr. Chopp's diagnosis with Mild Cognitive Impairment and Alzheimer's in 2019, she was a widely published author, editor, and renowned academic in the fields of education, philosophy, religion, and feminism.

She served as the 18th and first female chancellor of the University of Denver. She also served as president of Swarthmore College and Colgate University, as Provost at Emory University, and as Dean of Divinity at Yale University. Dr. Chopp is also an ordained United Methodist Minister.

Since retiring, Dr. Chopp devotes every day to living with joy. She enjoys painting classical portraits and abstracts, hiking in the Colorado mountains with Buhdy, her dog, and laughing and loving Fred, her husband, as well as reading and spending time with friends and family.

Dr. Chopp defies the stigma surrounding Alzheimer’s by living with joy. Her goal is to help everyone understand that those with this disease can find ways to contribute and flourish.

Read more

This Speaker's Sessions

PANEL
Wednesday Oct. 16
-
1:30–2:20 PM ET
Watch Replay
Now Live!

The Patient Pathway: Beginning the Journey with Cognitive Impairment

For many diseases, well-defined diagnostic and care pathways guide patients, doctors, and caregivers through the patient journey. That is not the case for Alzheimer’s. This panel will discuss what that pathway should look like, starting from the moment a patient prepares to discuss their brain health with their doctor, through subsequent referrals to specialists and treatment options, to exploring potential involvement in clinical trials. Key Question: What needs to happen so that people with cognitive impairment have a smooth path to a reliable diagnosis, appropriate treatment, and access to clinical trials?

View SessionWatch Replay